

ASCO 2011

Friday, June 3, 2011

2:00 PM - 6:00 PM

POSTER DISCUSSION SESSION

Head and Neck Cancer

Brd. 22 Human papillomavirus (HPV)–related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT. (Abstract #5528)

B. Pajares, J. Trigo Perez, M. D. Toledo, M. Alvarez, L. Perez-Villa, C. Gonzalez-Hermoso, A. Rueda, J. A. Medina, B. Jimenez, J. Jerez, L. Perez, E. Alba

2:00 PM - 6:00 PM

POSTER DISCUSSION SESSION

Leukemia, Myelodysplasia, and Transplantation

Brd. 10 Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies. (Abstract #6518)

M. Talpaz, N. P. Shah, M. W. Deininger, M. J. Mauro, I. W. Flinn, S. Lustgarten, W. Lindmark, J. M. Gozgit, T. Clackson, C. D. Turner, F. G. Haluska, H. Kantarjian, J. E. Cortes

Brd. 20 A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53-defective chronic lymphocytic leukemia (CLL). (Abstract #6528)

J. E. Castro, L. S. Schwartzberg, J. Pinilla-Ibarz, T. J. Kipps, M. J. Cantwell

Saturday, June 4, 2011

8:00 AM - 9:15 AM

CLINICAL PROBLEMS IN ONCOLOGY SESSION

How to Manage Challenging Cases of Urothelial Cancer (C02)—Ticketed Session

Track(s): Genitourinary Cancer, Geriatric Oncology

Joaquim Bellmunt, MD, PhD—Chair

University Hospital del Mar-IMIM

Treatment Options for a Patient with Locally Advanced but Unresectable Bladder Cancer and for a Patient with Muscle-invasive but with Mixed Histology or Predominantly Nontransitional Cell

8:00 AM - 12:00 PM

GENERAL POSTER SESSION

Gastrointestinal (Colorectal) Cancer

Brd. 11H Three-year outcomes of GCR-3: A phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer. (Abstract #3552)

C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont, R. Vera, M. P. Escudero, J. Maurel, J. Aparicio

Brd. 13G Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS). (Abstract #3567^)

S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet, D. Cunningham, F. Xu, K. Krishnan, J. Douillard

8:00 AM - 12:00 PM

GENERAL POSTER SESSION

Gastrointestinal (Noncolorectal) Cancer

Brd. 31H Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4074)

R. S. Finn, R. Poon, T. Yau, H. Klumpen, L. Chen, Y. Kang, T. Kim, C. Gomez-Martin, C. Rodriguez-Lope, T. Kunz, T. Paquet, K. Asubonteng, R. E. Winkler, O. Anak, D. B. Sellami, J. Bruix

Brd. 32E Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. (Abstract #4079)

A. J. Zurita, J. Heymach, M. Khajavi, L. Tye, X. Huang, M. Kulke, H. Lenz, N. J. Meropol, W. Carley, S. E. DePrimo, C. S. Harmon

Brd. 36G Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). (Abstract #4113)

D. E. Castellano, J. Capdevila, R. Salazar, J. Sastre, V. Alonso, M. Llanos, R. Garcia-Carbonero, A. Abad, I. Sevilla, I. Duran, Spanish Neuroendocrine Tumor Group (GETNE)

Brd. 37E Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC). (Abstract #4119)

Y. Kang, A. Ohtsu, E. Van Cutsem, L. Roman, J. Nunes, C. Li, D. Otero, F. Rivera, G. Aprile, P. R. Pimentel Alvarez, M. H. Moehler, J. Wu, B. Langer, M. A. Shah

Brd. 37H Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. (Abstract #4122)

M. Alsina, A. H. Ko, M. Garcia De Paredes, F. Rivera, L. S. Schwartzberg, A. Fattaey, L. A. Kunkel, J. Tabernero, J. A. Ajani

8:00 AM - 1:00 PM

POSTER DISCUSSION SESSION

Brd. 15 Bevacizumab changes in patients with naive, stage II-III breast cancer assessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT.

(Abstract #2529)

V. Boni, I. Dominguez, M. J. Garcia Velloso, J. Lopez Vega, P. Martinez, A. Plazaola, B. Hernando, A. Llombart Cussac, J. Lao, R. S. Gomez, I. Alvarez, J. J. Illarramendi, E. G. Calvo, S. Morales Murillo, T. Puertolas, L. J. Pina, E. Bernedo, G. Palacios, S. J. Scherer, J. Garcia-Foncillas

8:00 AM - 1:00 PM

POSTER DISCUSSION SESSION

Lymphoma and Plasma Cell Disorders

Brd. 11 Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). (Abstract #8025)

M. Wang, W. Bensinger, T. Martin, M. Alsina, D. S. Siegel, N. Y. Gabrail, P. Hari, S. Singhal, R. A. Vescio, S. E. Assouline, L. A. Kunkel, M. Vallone, A. Wong, R. Niesvizky

Brd. 13 PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. (Abstract #8027)

D. S. Siegel, T. Martin, M. Wang, R. Vij, S. Lonial, V. Kukreti, N. J. Bahlis, M. Alsina, G. Somlo, F. Buadi, F. J. Reu, K. W. Song, L. A. Kunkel, A. Wong, M. Vallone, R. Z. Orlowski, A. K. Stewart, S. Singhal, S. Jagannath, A. J. Jakubowiak, The Multiple Myeloma Research Consortium (MMRC)

8:00 AM - 1:00 PM

POSTER DISCUSSION SESSION

2:45 PM A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. (Abstract #3509)

T. Andre, E. Van Cutsem, H. Schmoll, J. Tabernero, S. Clarke, M. J. Moore, D. Cunningham, T. H. Cartwright, J. R. Hecht, F. Rivera, S. Im, G. Bodoky, R. Salazar, F. Maindrault-Goebel, E. Shmueli, E. Bajetta, M. Makrutzki, A. Shang, A. De Gramont, P. M. Hoff

Discussion

3:15 PM Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC).(Abstract #3510^)

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet, D. Cunningham, F. Xu, K. Krishnan

1:15 PM - 2:45 PM

CLINICAL SCIENCE SYMPOSIUM

Ovarian Cancer: Novel Approaches to Improve Treatment Outcomes

2:15 PM Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab (MIMOSA) Trial. (Abstract #LBA5002)

J. Pfisterer, J. S. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska, E. Pujade-Lauraine, G. Scambia, J. B. Vermorken, C. Simonelli, M. Bertolotti, A. Capriati, P. Sabbatini, AGO-OVAR, COGI, GEICO, GINECO

2:00 PM - 6:00 PM

POSTER DISCUSSION SESSION

Breast Cancer—Triple-negative/Cytotoxics/Local Therapy

Brd. 5 Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in

patients with basal-like breast cancer. GEICAM 2006-03: A multicenter, randomized phase II study. (Abstract #1015)

E. Alba, J. Chacon, A. Lluch, L. Garcia-Estevez, A. Anton, B. Cirauqui, J. Lopez Garcia-Asenjo, E. M. Carrasco, C. Rodriguez, M. Escudero, A. Sanchez, N. Ribelles, C. Romero, J. Alvarez, J. Albanell, on behalf of Spanish Breast Cancer Research Group (GEICAM)

Brd. 12 Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts). (Abstract #1022)

M. Ruiz-Borrego, C. H. Barrios, A. Lluch, J. Bines, J. Segalla, A. Ruiz, L. Torrecillas, A. Llombart-Cussac, R. Torres, J. Garcia Saenz, J. Lopez Garcia-Asenjo, H. L. Gomez, J. De la Haba, S. Reyes, E. Martinez, J. Baena, L. Perez-Michell, A. Rodriguez-Lescure, A. Anton, M. Martin, on behalf of CIBOMA/GEICAM

2:00 PM - 6:00 PM

POSTER DISCUSSION SESSION

Developmental Therapeutics—Experimental Therapeutics

Brd. 1 First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. (Abstract #3011)

J. Rodon Ahnert, J. Baselga, E. Calvo, J. Seoane, I. Brana, E. Sicart, I. Gueorguieva, A. Cleverly, M. M. Lahn, S. Pillay, M. Holdhoff, J. O. Blakeley, M. A. Carducci

Brd. 4 A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. (Abstract #3014)

C. M. Rudin, A. Jimeno, W. H. Miller Jr., B. J. Eigl, S. N. Gettinger, A. L. Chang, K. Faia, J. Sweeney, G. Loewen, R. W. Ross, G. J. Weiss

Brd. 11 A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. (Abstract #3021)

V. Moreno Garcia, R. D. Baird, K. J. Shah, B. Basu, N. Tunariu, M. Blanco, P. A. Cassier, J. V. Pedersen, M. Puglisi, D. Sarker, D. Papadatos-Pastos, A. G. Omlin, A. Biondo, J. A. Ware, H. Koeppen, G. G. Levy, K. E. Mazina, J. S. De Bono

Brd. 12 First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068. (Abstract #3022)

J. Tabernero, C. Saura, D. Roda Perez, R. Dienstmann, S. Rosello, L. Prudkin, J. A. Perez-Fidalgo, B. Granñá, C. Jones, L. Musib, Y. Yan, P. H. Patel, J. Baselga, A. Cervantes

Brd. 15 Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. (Abstract #3025)

A. Cervantes, M. Alsina, J. Tabernero, J. R. Infante, P. LoRusso, G. Shapiro, L. G. Paz-Ares, R. Falzone, J. Hill, J. Cehelsky, A. White, I. Toudjarska, D. Bumcrot, R. Meyers, G. Hinkle, N. Svrzikapa, D. W. Sah, A. Vaishnav, J. Gollob, H. A. Burris III

2:00 PM - 6:00 PM

POSTER DISCUSSION SESSION

Tumor Biology

Brd. 1 Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). (Abstract #10509)

J. M. Balko, R. S. Cook, T. W. Miller, N. E. Bholá, M. Sanders, N. M. Granja-Ingram, V. Sanchez, I. M. Meszoely, J. Salter, M. Dowsett, K. Stemke-Hale, A. M. Gonzalez-Angulo, G. B. Mills, C. L. Arteaga

2:00 PM - 6:00 PM

GENERAL POSTER SESSION

Cancer Prevention/Epidemiology

Brd. 4H Gynecological cancer screening in women at high risk of Lynch syndrome. (Abstract #1559)

C. Guillen-Ponce, C. Martinez-Sevila, R. Perea, M. Arenas, M. Molina-Garrido, M. Goicoechea, D. Salas, A. Carrato, Hereditary Cancer Group of the Comunidad Valenciana (Spain)

2:00 PM - 6:00 PM

GENERAL POSTER SESSION

Head and Neck Cancer

Brd. 17D High-grade transformation in acinic cell carcinoma of the salivary glands: A rare but important clinical entity. (Abstract #5581)

K. A. Price, W. Shon, J. A. Davidson, J. E. Lewis, D. L. Price, J. J. Garcia

Brd. 19A Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. (Abstract #5594)

B. Jimenez, J. Trigo Perez, M. Saez Medina, C. Quero Blanco, B. Pajares, A. Rueda, E. Alba

2:00 PM - 6:00 PM

GENERAL POSTER SESSION

Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell

Brd. 21A Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts). (Abstract #7037)

E. Felip, M. Salcedo, N. Murtra-Garrell, A. Navarro, C. Teixido, J. Hernandez-Losa, S. Cedres, P. Martinez, E. Lopez, M. Montero, V. Freixinos, G. Argiles, I. Nuñez, V. Peg, E. Pallisa, M. Canela, J. Tabernero, S. Ramon y Cajal, N. Tallada

Brd. 23E PI3K pathway and downstream signaling analysis in malignant pleural mesothelioma (MPM). (Abstract #7057)

S. Cedres Perez, M. Montero, D. Torrejon, P. Martinez, V. Freixinos, N. Mulet-Margalef, G. Argiles, I. Nuñez, E. Lopez, L. Prudkin, M. Salcedo, N. Tallada, S. Ramon y Cajal, E. Felip

2:00 PM - 6:00 PM

GENERAL POSTER SESSION

Lung Cancer—Metastatic/Non-small Cell

Brd. 35B AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)- pem: Interim safety data. (Abstract #7562)

F. Barlesi, A. Scherpereel, R. Gervais, V. A. Gorbunova, A. Vikström, M. J. Ahn, J. H. Kim, A. Chella, J. Aerts, N. Ferrer, J. M. Trigo Perez, B. Lutiger, A. Rittmeyer

Brd. 35F ALK rearrangement in a selected population of advanced non-small cell lung cancer patients: FISH and immunohistochemistry diagnostic methods, prevalence and clinical outcomes. (Abstract #7566)

P. Martinez, J. Hernandez-Losa, J. Castellvi, N. Tallada, S. Cedres, M. Montero, V. Rodriguez-Freixinos, I. Nuñez, G. Argiles, N. Mulet-Margalef, D. Torrejon, S. Ramon y Cajal, E. Felip

Brd. 37G Circulating endothelial cells, endothelial progenitor cells, microparticles, and markers of inflammation and coagulation in advanced non-small cell lung cancer. (Abstract #7583)

T. Fleitas, G. Reynes, V. Martinez-Sales, V. Vila, E. Reganon, D. Mesado, M. Martin, J. Gómez-Codina, J. Montalar

Brd. 38D Mutations of the catalytic subunit α of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #7588)

E. Carcereny, M. A. Molina, J. Sanchez, J. Bertran-Alamillo, C. Mayo, E. Aldeguer, A. Gimenez Capitan, Z. Yeste, C. Costa, S. Benlloch, A. Martinez, C. Buges, J. Bosch, D. Isla, M. Domine, M. Provencio, C. Camps, M. Taron, R. Rosell

Brd. 39A DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #7593)

J. Wei, J. Ramirez, M. Taron, J. Sanchez, S. Benlloch, R. Rosell, M. Botia, M. Perez-Cano, P. Mendez, M. Tierno, C. Queralt, I. de Aguirre, B. Sanchez, A. Martinez, C. Buges, J. Bosch, B. Massuti, C. Camps, T. Moran

Brd. 39D The surfactant protein B (SFTPB) as a surrogate of circulating tumor cells (CTC) with prognostic value in advanced-stage NSCLC. (Abstract #7596)

R. Sirera, E. Jantus-Lewintre, A. Timon, M. Uso, A. Berrocal, S. Borrego, G. Marcaida, E. Sanmartin, R. Rosell, C. Camps

2:00 PM - 6:00 PM

GENERAL POSTER SESSION

Patient and Survivor Care

Brd. 51B Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis. (Abstract #9115)

G. E. Richardson, T. E. Ciuleanu, L. Costa, S. J. Gans, J. Garcia Saenz, V. Hirsh, V. Hungria, M. Krzakowski, C. Manegold, H. Nahi, S. Novello, A. L. Petzer, M. E. Rader, P. Solal-Celigny, S. Vadhan-Raj, J. F. Vansteenkiste, P. J. Woll, C. Ke, K. Chung, H. Yeh

3:00 PM - 6:00 PM

ORAL ABSTRACT SESSION

Gynecologic Cancer

5:00 PM A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma. (Abstract #5009)

A. M. Oza, A. Poveda, A. R. Clamp, S. Pignata, G. Scambia, J. Del Campo, M. McCormack, L. Sevcik, B. M. Schwartz, S. Guan, R. Lee, J. D. Cheng, F. G. Haluska

4:30 PM - 6:00 PM

CLINICAL SCIENCE SYMPOSIUM

Finding the Targets, Restoring the Vision

5:00 PM A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. (Abstract #3501)

D. J. Watkins, J. Tabernero, H. Schmoll, T. Trarbach, F. J. Ramos, J. Howe, H. M. Brown, J. Clark, K. Hsu, B. D. Lu, D. Cunningham

Sunday, June 5, 2011

8:00 AM - 11:00 AM

ORAL ABSTRACT SESSION

Central Nervous System Tumors

Brd. 6E Final results of a risk-adapted policy of adjuvant chemotherapy (ACT) in patients with invasive bladder carcinoma (IBC). (Abstract #4613)

J. Arranz Arijia, Y. Jerez Gilarranz, A. Soria Lovelle, C. Lo'pez Lo'pez, P. Sabin Dominguez, M. Riesco, J. Adeva Alfonso, D. Urosa Velasco, E. Lo'pez Jua' rez, R. Gonza' lez Beca, M. Martin

Brd. 7C Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in lymph node-positive prostate cancer (PCa). (Abstract #4619)

L. C. Pagliaro, A. J. Zurita, J. C. Araujo, J. F. Ward, J. W. Davis, C. A. Pettaway, S. Tu, J. Kim, P. Dieringer, C. Logothetis, L. L. Pisters

Brd. 11D 9q32-q33.1 amplification as a prognostic factor for overall survival in metastatic germ cell tumors. (Abstract #4652)

J. M. Piulats, A. Vidal, M. Nadal, A. Pisa, J. R. Germa-Lluch, E. Condom, A. Villanueva, X. Garcia del Muro

Brd. 12H Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium. (Abstract #4664)

D. J. George, S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, A. J. Armstrong, R. J. Varley, J. Madden, J. W. Moul

8:00 AM - 12:00 PM

GENERAL POSTER SESSION

Gynecologic Cancer

Brd. 17G Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301. (Abstract #5067)

A. Poveda, B. J. Monk, S. B. Kaye, J. B. Vermorken, I. B. Vergote, I. B. Runnebaum, E. Pujade-Lauraine, T. V. Parekh, A. Nieto, J. Gomez, Y. C. Park, N. Colombo

Brd. 18D Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. (Abstract #5072)

K. M. Esselen, N. Rodriguez, N. S. Horowitz, S. M. Campos

8:00 AM - 12:00 PM

GENERAL POSTER SESSION

Melanoma/Skin Cancers

Brd. 24D An analysis of altered melanoma matrix metalloproteinase-23 (MMP-23) expression and response to immune biologic therapy. (Abstract #8541)

M. Krogsgaard, M. W. Ma, E. B. Friedman, E. Vega-Saenz de Miera, F. Darvishian, A. Perez-Garcia, R. S. Berman, R. L. Shapiro, P. J. Christos, I. Osman, A. C. Pavlick

Brd. 32D Feasibility and reliability of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma. (Abstract #8575)

M. D. Lozano, T. Labiano, J. I. Echeveste, M. Montana, N. Gomez, M. F. Sanmamed, A. Gurrpide, M. A. Idoate, S. Martin-Algarra

8:00 AM - 12:00 PM

GENERAL POSTER SESSION

Sarcoma

Brd. 44A Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study. (Abstract #10034)

J. Blay, S. P. Chawla, J. Martin Broto, E. Choy, M. Dominkus, J. Engellau, R. Grimer, R. M. Henshaw, E. Palmerini, P. Reichardt, P. Rutkowski, K. M. Skubitz, D. M. Thomas, Y. Zhao, Y. Qian, I. A. Jacobs

Brd. 45A High-dose chemotherapy plus autologous stem cell transplantation (HDCT/SCT) in patients with sarcoma: A single institution experience. (Abstract#10042)

A. Stradella, A. Lopez-Pousa, M. Quintana, P. Murata, M. Ortin, O. Gallego, I. Sullivan, L. Robert, A. Sebio, I. Gracia, J. De Vega, A. Barnadas

Brd. 45F KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. (Abstract#10047)

J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, J. Rubio, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, M. Ramirez, R. Cubedo, J. Lopez-Guerrero, Spanish Group for Sarcoma Research

(GEIS)

Brd. 46F Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study. (Abstract #10055)

J. Rubio´ , J. Martinez-Trufero, A. Lopez-Pousa, X. Garcia del Muro, J. Fra, A. Redondo, N. Lainez, A. Poveda, A. Casado, C. M. Valverde, A. De Juan, I. Sevilla, R. Andres, J. Cruz, M. Safont, J. Martin Broto, X. Garcia-Albeniz, J. Maurel

Brd. 48G A phase II study of a new formulation of nonpegylated liposomal doxorubicin(doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial. (Abstract#10072)

A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balan˜a´ , J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo, J. Blay

8:00 AM - 12:30 PM

POSTER DISCUSSION SESSION

Patient and Survivor Care

Brd. 10 Vitamin D repletion and prevention of bone loss in nonosteoporotic women with breast cancer. (Abstract #9026)

S. Servitja, D. Prieto-Alhambra, M. Martinez-Garcia, L. Garrigos, M. J. Pena, A. Diez-Perez, J. Albanell, X. Nogues, I. Tusquets

Brd. 17 Molecular diagnosis of bacteriemia in patients with neutropenic febrile oncohematologic. (Abstract #9033)

E. Gimeno, L. Sorli, E. Abella, A. Alvarez-Larran, J. Horcajada, L. Garrigos, A. Taus, A. Salar, B. Sanchez, C. Pedro, C. Besses, M. Salvado

10:45 AM First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors. (Abstract #3006^)

S. O. Dolly, J. Albanell, F. Kraeber-Bodere, U. Banerji, R. Bahleda, M. Martinez Garcia, Z. X. Xu, E. Guarin, J. Tessier, E. Shochat, J. Deutsch, S. Blotner, V. Meresse, J. Soria

9:30 AM - 12:30 PM

ORAL ABSTRACT SESSION

Developmental Therapeutics—Experimental Therapeutics

10:45 AM First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors. (Abstract #3006^)

S. O. Dolly, J. Albanell, F. Kraeber-Bodere, U. Banerji, R. Bahleda,

M. Martinez Garcia, Z. X. Xu, E. Guarin, J. Tessier, E. Shochat, J. Deutsch, S. Blotner, V. Meresse, J. Soria

9:30 AM - 12:30 PM

ORAL ABSTRACT SESSION

Lung Cancer—Metastatic/Non-small Cell

9:30 AM Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. (Abstract #7503)

R. Rosell, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, F. Cardenal, R. Garcia Gomez, C. Pallares, J. Sanchez, R. Porta, M. Cobo, M. Di Seri, P. Garrido Lopez, A. Insa, F. De Marinis, R. Corre, M. Carreras, E. Carcereny, M. Taron, **L. G. Paz-Ares**, Spanish Lung Cancer Group

11:30 AM PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #CRA7510)

L. G. Paz-Ares, F. De Marinis, M. Dediu, M. Thomas, J. Pujol, P. Bidoli, O. Molinier, T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. John, N. Chouaki, A. Zimmerman, C. M. Visseren Grul, C. Gridelli

9:30 AM - 12:30 PM

ORAL ABSTRACT SESSION

Myeloma

5:00 PM Final results of a translational phase I study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. (Abstract #3001^)

T. A. Yap, L. Yan, A. Patnaik, **D. Olmos**, I. Fearen, R. D. Baird, K. P. Papadopoulos, N. Tunariu, A. Biondo, H. Keilhack, **L. M. Delgado**, A. Taylor, S. C. Blackman, C. L. Carpenter, S. Decordova, S. Heaton, M. D. Garrett, D. Sullivan, J. S. De Bono, A. W. Tolcher

4:30 PM - 6:00 PM

CLINICAL SCIENCE SYMPOSIUM

Predictive Markers in Breast Cancer: How Many Tests Do We Need, and What Do They Tell Us?

5:15 PM Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. (Abstract #502)

A. Prat, J. S. Parker, C. Fan, M. Cheang, L. D. Miller, J. Bergh, S. K. Chia, P. S. Bernard, T. O. Nielsen, M. J. Ellis, L. A. Carey, C. M. Perou

Monday, June 6, 2011

8:00 AM - 11:00 AM

ORAL ABSTRACT SESSION

Genitourinary (Nonprostate) Cancer

9:45 AM A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). (Abstract #4509)

R. De Wit, I. A. Skoneczna, K. Gedske Daugaard, M. de Santis, A. Garin, N. Aass, J. A. Witjes, P. Albers, J. White, J. Germa-Lluch, S. Osanto, S. Marreaud, L. Collette

Brd. 8C NAD(P)H oxidase genetic polymorphisms and anthracyclines-induced cardiac lesions in patients with cancer. (Abstract #2596)

A. Cascales, F. Pastor, B. Sanchez-Vega, J. Corral, A. Vicente, T. Garcia, V. Vicente, F. Ayala

8:00 AM - 12:00 PM

GENERAL POSTER SESSION

Developmental Therapeutics—Experimental Therapeutics

Brd. 11H Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. (Abstract #3043)

B. Grana, H. A. Burris III, J. Rodon Ahnert, A. R. Abdul Razak, M. J. De Jonge, F. Eskens, L. L. Siu, Q. C. Ru, N. F. Homji, D. Demanse, E. Di Tomaso, J. G. Cosaert, C. Quadt, J. Baselga, J. C. Bendell

Brd. 13E Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the

novel dual PI3K/mTOR inhibitor BEZ235. (Abstract #3056)

D. Bottino, J. Tabernero, H. A. Burris III, C. Britten, L. Chen, J. C. Bendell, O. Chiparus, V. Duval, E. Di Tomaso, C. Sarr, W. Hackl, J. Baselga, J. Rodon Ahnert

Brd. 14F Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. (Abstract #3065)

I. Garrido-Laguna, R. Kurzrock, J. J. Wheler, G. S. Falchook, S. A. Piha-Paul, S. Fu, A. Naing, C. Hinojosa, R. Mistry, A. Scamardo, K. S. Culotta, S. Ekmekcioglu, S. Wen, L. H. Camacho, S. P. Ivy, D. S. Hong

Brd. 14G A dose-escalation study with the novel formulation of the oral pan-class IPI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with

advanced solid tumors. (Abstract #3066)

J. D. Peyton, J. Rodon Ahnert, H. Burris, C. Britten, L. Chen, J. Tabernero, V. Duval, N. Rouyre, A. P. Silva, C. Quadt, J. Baselga

Brd. 15A Update on a phase I pharmacologic and pharmacodynamic study of MK- 1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. (Abstract #3068)

J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, S. Leijen, S. M. Tolaney, I. Diaz-Padilla, R. K. Ramanathan, T. Demuth, J. Viscusi, J. D. Cheng, R. Lam, Y. Xu, A. M. Oza

Brd. 17A Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study. (Abstract #3084)

P. A. Cassier, V. Moreno Garcia, C. Gomez-Roca, D. Olmos, R. Morales, G. Del Conte, E. Gallerani, A. Brunetto, P. Schoffski, S. Marsoni, J. H. Schellens, N. Penel, E. E. Voest, T. Evans, R. Plummer, R. H. Wilson, J. Soria, J. Tabernero, J. Verweij, S. B. Kaye, European Drug Development Network

Brd. 17F Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors. (Abstract #3089)

R. Dienstmann, A. W. Tolcher, K. P. Papadopoulos, D. W. Rasco, J. Tabernero, I. Brana, A. Piera, N. Skartved, H. Aladdin, J. Petersen, A. Patnaik

Brd. 19B Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors. (Abstract #3101)

W. Ma, W. A. Messersmith, G. K. Dy, E. Freas, A. Whitworth, F. Wilhelm, S. G. Eckhardt, A. A. Adjei, A. Jimeno

Brd. 19F Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P). (Abstract #3105)

J. A. Lopez-Martin, M. Vidal Losada, J. Cortes, B. Bermejo, A. Lluch Fernandez, M. Learoyd, A. Saunders, M. Stuart, J. Baselga

Brd. 20H Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #10541)

S. Viteri, R. Rosell, C. Costa, M. Taron, J. Sanchez, S. Benlloch, T. Moran, B. Massuti, C. Camps, M. Majem, E. Carcereny, F. Cardenal, A. Gasco, N. Mederos, I. Magri, C. D. Rolfo, M. Garcia-Campelo, A. Gimenez Capitan, I. de Aguirre, C. Queralt

Brd. 28A SOX2-related micrnas, miR-145 and miR-367, as prognostic markers of time to recurrence (TTR) in surgically resected non-small cell lung cancer (NSCLC) patients (p). (Abstract #10583)

A. Navarro, M. Campayo, N. Vinolas, V. Ciria, T. Diaz, R. M. Marrades, L. Molins, J. Ramirez, M. Monzo

Brd. 28C ALK chromosomal alterations in neuroendocrine tumors. (Abstract #10585)

C. Montagut, E. Arriola, A. B. Galvan, F. G. Rojo, M. Salido, M. Gallen, M. Garcia,

A. Martinez, F. Pons, S. Servitja, M. Iglesias, S. Menendez, S. Serrano, F. Sole, A. Rovira, J. Albanell, J. Bellmunt

Brd. 29B A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding site of KRT81 and time to recurrence (TTR) in patients (p) with surgically resected non-small cell lung cancer (NSCLC). (Abstract #10587)

M. Campayo, A. Navarro, N. Vinolas, R. Tejero, C. Munoz, T. Diaz, R. M. Marrades, M. L. Cabanas, J. M. Gimferrer, J. Ramirez, P. Gascon, M. Monzo

Brd. 37D A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER₊) breast cancer. (Abstract #TPS110)

S. Ebbinghaus, J. L. Blum, J. Cortes, H. S. Rugo, C. Swanton, L. Eaton, Y. Song, T. Zhang, J. Baselga

Brd. 39B Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). (Abstract #TPS124)

J. Baselga, L. S. Schwartzberg, O. Petrenciuc, M. Shan, W. J. Gradishar

Brd. 42G Integrative and multidisciplinary clinical trial using imaging, molecular, and dynamic biomarkers to predict bevacizumab plus chemotherapy response in breast cancer. (Abstract #TPS153)

J. Lopez Vega, E. G. Calvo, A. Plazaola, B. Hernando, S. Morales Murillo, A. Anton, R. S. Gomez, I. Alvarez, J. J. Illarramendi, A. De Juan, P. Martinez, A. Llombart, S. J. Scherer, L. Sabariz, A. la Huerta, L. J. Pina, I. Dominguez, M. J. Garcia Velloso, V. Boni, J. Garcia-Foncillas

Brd. 44B PULSE: An open-label, phase II study assessing double positivity (phosphoinosulin- growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. (Abstract #TPS164)

J. Maurel, X. Garcia-Albeniz, C. Me´ndez Me´ndez, M. Martin-Richard, C. Pericay, R. Vera, J. Aparicio, M. Rubini, M. Cuatrecasas, on behalf of the GEMCAD Cooperative Group

Brd. 44G IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced gastroesophageal cancer. (Abstract #TPS169)

S. A. Szyldergemajn, A. Gonc¸alves, J. Metges, K. Gunzer, C. Montagut, R. Salazar, M. Alsina, T. Evans, D. Swinson, R. D. Petty, H. Singer, C. M. Kahatt

Brd. 45A PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment. (Abstract #TPS171)

J. Capdevila, A. Teule, D. E. Castellano, J. Sastre, R. Garcia-Carbonero, I. Sevilla, I. Duran, P. Escudero, J. Fuster, E. Grande Pulido

Brd. 48A A phase II study to evaluate the efficacy and safety of catumaxomab as consolidation treatment in patients with epithelial ovarian cancer in second or third complete remission. (Abstract #TPS195)

A. M. Oaknin, L. Chiva, I. Romero, A. Romero, M. M. Essing, A. González-Martíñ, GEICO

Brd. 49F SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIa non-small cell lung cancer. (Abstract #TPS208)

B. Massuti, U. Jimenez, J. M. Rodríguez Paniagua, Y. W. Pun, M. Cobo, E. Carcereny Costa, R. Arrabal, J. Astudillo, I. Barneto, R. De Las Penas, C. Baamonde, G. Sales, J. Gonzalez-Larriba, G. Lopez-Vivanco, F. Hernando-Trancho, J. Pac, A. Artal-Cortes, J. Rivas, R. Rosell, J. Sanchez, Spanish Lung Cancer Group / SLCG-GECP

8:00 AM - 12:30 PM

POSTER DISCUSSION SESSION

Gastrointestinal (Colorectal) Cancer

Discussion

12:00 PM Josep Tabernero, MD (Abstracts #3523–3528)

Vall d'Hebron University Hospital

Brd. 2 EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. (Abstract #3513)

A. Dewdney, J. Capdevila, B. Glimelius, A. Cervantes, D. M. Tait, G. Brown, A. Wotherspoon, D. Gonzalez de Castro, Y. Chua, R. Wong, Y. Barbachano, J. R. Oates, I. Chau, D. Cunningham

Brd. 23 The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer. (Abstract #3534)

I. Simon, S. Tian, V. Moreno, P. Roepman, J. Tabernero, M. Snel, T. Macarulla, L. van't Veer, R. Bernards, G. Capella

8:00 AM - 12:30 PM

POSTER DISCUSSION SESSION

Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell

Discussion

11:40 AM Enriqueta Felip, MD (Abstracts #7011–7015)

Vall d'Hebron University Hospital

9:30 AM - 12:30 PM

ORAL ABSTRACT SESSION

Breast Cancer—Triple-negative/Cytotoxics/Local Therapy

11:30 AM Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009–05 study. (Abstract #1008)

M. Martin, N. Martinez, M. Ramos, L. Calvo, A. Lluch, P. Zamora, M. Munoz-Mateu, D. Caronia, E. M. Carrasco, J. Garcia Saenz, A. Casado, I. Chaco'n, B. Hernando, M. Ruiz-Borrego, A. Gonzalez-Neira

1:00 PM - 5:00 PM

GENERAL POSTER SESSION

Breast Cancer—HER2/ER

Brd. 2A A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). (Abstract #544)

V. Dieras, J. Jassem, L. Y. Dirix, J. P. Guastalla, P. Bono, S. A. Hurvitz, A. Gonc¸alves, G. Romieu, S. A. Limentani, G. H. Jerusalem, K. Lakshmaiah, H. H. Roche, P. Sa´nchez-Rovira, T. Pienkowski, M. Segur´-Palmer, A. Li, Y. Sun, C. A. Pickett-Gies, H. Wildiers

Brd. 3D PAM50 intrinsic subtyping and pathological responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. (Abstract #554)

P. Gomez Pardo, A. Prat, G. Bianchini, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, F. Va´zquez-Mazo´n, L. Gianni, J. Baselga

Brd. 3F Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2–98) of node-positive (N₊) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (Abstract #556)

S. Loi, R. Salgado, F. Piette, N. Sirtaine, F. Van Eenoo, R. Kammler, G. Rouas, P. A. Francis, J. Crown, B. Nordenskjold, J. Gutierrez, M. Andersson, M. M. Vila, R. Jakesz, G. Viale, E. M. Quinaux, A. Di Leo, S. Michiels, C. Sotiriou, M. J. Piccart-Gebhart

Brd. 7H Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. (Abstract #590)

S. Modi, C. Saura, C. A. Henderson, N. U. Lin, R. L. Mahtani, J. Goddard, E. Rodenas, J. O'Shaughnessy, J. Baselga

Brd. 8D Association between bone turnover markers and skeletal-related events in patients with breast cancer and bone metastases on treatment with

bisphosphonates (ZOMAR study results at 9 months of follow-up). (Abstract #594)

A. Barnadas, C. De la Piedra, C. Crespo, P. Gomez Pardo, L. Calvo, E. G. Calvo, M. Ruiz-Borrego, J. Rifa, L. Manso, A. Anton, M. Codes, M. Margeli, A. Murias, J. Salvador, M. Seguí-Palmer, A. De Juan, J. Gavila, D. Perez, M. Luque, I. Tusquets

Brd. 10E Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial. (Abstract #611)

P. S. Bernard, C. Davis, B. Munarriz, I. J. Stijleman, M. Ruiz-Borrego, M. T. Ebbert, A. Rodriguez-Lescure, R. R. Bastien, C. Crespo, C. M. Perou, C. Rodriguez, F. I. Aranda, V. Furio, I. Alvarez, M. Seguí, E. Alba, A. Anton, E. M. Carrasco, R. Caballero, M. Martin

Brd. 11B Prognostic impact of phosphorylated HER2 in HER2-positive primary breast cancer using reverse-phase protein array. (Abstract #616)

N. Hayashi, T. Iwamoto, A. M. Gonzalez-Angulo, J. Ferrer-Lozano, A. Lluch, N. Niikura, C. Bartholomeusz, S. Nakamura, G. N. Hortobagyi, N. T. Ueno

Brd. 12H Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study. (Abstract #630)

J. De la Haba, A. Rodriguez-Lescure, J. Baena, J. Martin Liberal, S. Morales, J. Chacon, J. Lopez, I. Fernandez, D. Aguiar, A. Garcia-Palomo, R. Llorente, A. J. Barea, E. Alvarez, I. Blancas, Y. Fernandez, P. Sanchez Rovira, G. Vinyes

1:00 PM - 5:00 PM

GENERAL POSTER SESSION

Breast Cancer—Triple-negative/Cytotoxics/Local Therapy

Brd. 15H A randomized phase II study of pemetrexed-carboplatin and gemcitabinevinorelbine in patients with anthracycline- and taxane-pretreated advanced breast cancer. (Abstract #1051)

D. Amadori, I. La Torre, E. M. Carrasco, S. Roesel, R. Labianca, V. Moreau-A. Donnet, D. Desai, M. Martin

Brd. 17E Effect of neoadjuvant ixabepilone (Ixa) on cell cycle genes and on tumorinitiating cell (TIC) signature in breast cancer (BC). (Abstract #1064)

A. H. Chang, C. E. Horak, P. Mukhopadhyay, C. Lowery, J. Baselga, J. A. Sparano

Brd. 18G Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A). (Abstract #1074)

E. Muñoz-Couselo, J. M. Perez-Garcia, C. Saura, M. Vidal, M. Bellet Ezquerra,

J. Balman˜a, B. Gran˜a, P. Gomez Pardo, L. De Mattos-Arruda, S. Di Cosimo, S. Mun˜oz, O. Vidal, B. Garcia Castro, R. Espallargas, V. Esteban, J. Tabernero, J. Baselga, J. Cortes

Brd. 19F Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC). (Abstract #1081)

M. Oliveira, L. De Mattos-Arruda, G. Sa´nchez-Olle´, B. Gran˜a, J. Cortes, J. M. Perez-Garcia, E. Mun˜oz-Consuelo, M. Vidal, M. Bellet, S. Di Cosimo, P. Gomez Pardo, J. Rodon Ahnert, J. Hernandez-Losa, A. Vivancos, L. Prudkin, A. C. Aura, V. Serra, J. Baselga, J. Tabernero, C. Saura

Brd. 19H Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. (Abstract #1083)

L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L. D. Bosserman, A. J. A. Sparano, J. Baselga, P. Mukhopadhyay, V. Valero

Brd. 23E First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis. (Abstract #1112)

J. Salvador, A. Jaen, E. Ciruelos, M. Codes, M. Gil, A. Murias, A. Galan, J. De la Haba, C. Jara, J. L. Bayo, J. Baena, J. Casal, J. Mel, I. Blancas, E. Gonzalez, D. Perez, L. Manso

1:00 PM - 5:00 PM

GENERAL POSTER SESSION

Lymphoma and Plasma Cell Disorders

Brd. 46D Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/ relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. (Abstract #8056)

M. Cotto, F. Cabanillas, G. Garcia-Manero, H. Yang, M. Bruno, O. A. Pavia, E. Rivera, I. Liboy, M. Tirado-Gomez

2:00 PM - 6:00 PM

POSTER DISCUSSION SESSION

Gastrointestinal (Noncolorectal) Cancer

Brd. 11 Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. (Abstract #4018)

E. Van Cutsem, C. Boni, J. Tabernero, B. Massuti, D. A. Richards, H. Prenen, A. I. Steinberg, P. Rougier

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION
Tumor Biology

5:15 PM Screening for *PIK3CA* mutations, PTEN loss, and *RAS/RAF* mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. (Abstract #10507)

F. Janku, I. Garrido-Laguna, J. J. Wheler, D. S. Hong, A. Naing, G. S. Falchook, S. Fu, S. L. Moulder, R. Luthra, J. Lee, A. M. Tsimberidou, R. Kurzrock

Tuesday, June 7, 2011

8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION
Breast Cancer—HER2/ER

Brd. 10 Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays. (Abstract #521)

A. Guerrero-Zotano, J. Gavila, E. Folkerd, B. Ortiz, T. Labrador, F. Martinez, A. Garcia, M. Climent, V. Guillem, M. Dowsett, A. Ruiz

Brd. 18 Response to neoadjuvant trastuzumab and chemotherapy in ER₋ and ERHER2- positive breast cancers: Gene expression analysis. (Abstract #529)

G. Bianchini, A. Prat, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, F. J. Vazquez Mazon, J. Baselga, L. Gianni

8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION
Genitourinary (Nonprostate) Cancer

Brd. 14 Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group. (Abstract #4559)

J. Garcia-Donas, E. Esteban, L. J. Leandro-García, D. E. Castellano, A. Gonzalez del Alba, M. Climent, J. A. Arranz, E. Gallardo, J. Puente, J. Bellmunt, B. Mellado, E. Martínez, F. Moreno, A. Font, M. Robledo, C. Rodriguez de Antona, Spanish Oncology GenitoUrinary Group (SOGUG)

Brd. 23 Identification of *ALK* gene alterations in urothelial carcinoma (UC). (Abstract #4568)

J. Bellmunt, S. Selvarajah, S. Rodig, M. Salido, I. Costa, B. Bellosillo, L. Werner, C. Namgyal, F. A. Schutz, F. Pons, R. O'Brien, J. Barretina, S. Signoretti, M. Loda, J. Albanell, T. K. Choueiri, D. M. Berman, P. W. Kantoff, J. E. Rosenberg

11:30 AM - 12:45 PM

EDUCATION SESSIONS

Cancer Stem Cells as a Therapeutic Target: Fact or Fiction?

Location: S100a

Joan Seoane, PhD

Vall d'Hebron University Hospital, Institut d'Oncologia

Targeting Signaling Pathways That Mediate Cancer Stem Cell Survival